Can Cannabis Stocks Reverse Their Prolonged Downtrend?
Cannabis stocks like TLRY and GTBIF remain deep in years-long slump, but U.S. federal reform or global expansion could ignite a long-awaited rebound.
Harmony Biosciences Holdings, Inc. ( HRMY ) Misses Q2 Earnings and Revenue Estimates
Harmony Biosciences (HRMY) delivered earnings and revenue surprises of -12.82% and -1.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Stoke Therapeutics, Inc. ( STOK ) to Report a Decline in Earnings: What to Look Out for
Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harmony Biosciences Holdings, Inc. ( HRMY ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Harmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?
Strong Dupixent profits and rising Eylea HD demand may help Regeneron offset pressure in its Q2 earnings report.
Tenet Beats Q2 Earnings on Strong Patient Volumes, Hikes '25 EPS View
THC's Q2 earnings benefit on the back of strong volumes, facility buyouts, higher acuity and favorable payer mix. It currently expects 2025 adjusted EPS within $15.55-$16.21, up from the earlier view of $11.99-$13.12.
5 High Earnings Yield Stocks to Tap Into Value Investing Gains
Unlock value with IAG, PAGP, HOPE, COMM and HRMY, five stocks with high earnings yields and strong growth signals.
Why Harmony Biosciences ( HRMY ) is Poised to Beat Earnings Estimates Again
Harmony Biosciences (HRMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Reasons Growth Investors Will Love Harmony Biosciences ( HRMY )
Harmony Biosciences (HRMY) could produce exceptional returns because of its solid growth attributes.
HRMY vs. ILMN: Which Stock Should Value Investors Buy Now?
HRMY vs. ILMN: Which Stock Is the Better Value Option?
Does Harmony Biosciences ( HRMY ) Have the Potential to Rally 43.19% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 43.2% in Harmony Biosciences (HRMY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is Harmony Biosciences ( HRMY ) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment
HRMY isn't your typical cannabis play - its synthetic CBD gel targets rare brain disorders with no approved therapies.
Harmony Biosciences Holdings, Inc. ( HRMY ) Tops Q1 Earnings and Revenue Estimates
Harmony Biosciences (HRMY) delivered earnings and revenue surprises of 32.20% and 0.66%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Why Harmony Biosciences ( HRMY ) Could Beat Earnings Estimates Again
Harmony Biosciences (HRMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Cue Biopharma, Inc. ( CUE ) Report Negative Q1 Earnings? What You Should Know
Cue Biopharma (CUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play?
Both JAZZ and HRMY expect sales from neuroscience products to grow in 2025.
HRMY Down 10.8% in Six Months: How Should You Play the Stock?
A recent regulatory setback has hit Harmony Biosciences stock. We recommend prospective investors to wait for a while before turning positive.
Should Value Investors Buy Harmony Biosciences ( HRMY ) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Harmony Biosciences ( HRMY ) Q4 2024 Earnings Call Transcript
HRMY earnings call for the period ending December 31, 2024.
Harmony Biosciences Holdings, Inc. ( HRMY ) Tops Q4 Earnings and Revenue Estimates
Harmony Biosciences (HRMY) delivered earnings and revenue surprises of 14.86% and 0.14%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Harmony Biosciences ( HRMY ) Upgraded to Strong Buy: Here's Why
Harmony Biosciences (HRMY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
5 High Earnings Yield Value Stocks to Buy Amid Market Volatility
Volatility looms with sticky inflation, a slowing economy and Trump's trade policies. Buy high-earnings-yield stocks like NUS, HRMY, PAHC, DAN and NRG.
FOLD's Q4 Earnings Miss, Higher Product Sales Drive Revenue Growth
Amicus' fourth-quarter 2024 earnings miss estimates while revenues beat the same.
Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder - Harmony Biosciences ( NASDAQ:HRMY )
Harmony Biosciences received an FDA Refusal to File letter for pitolisant in idiopathic hypersomnia but plans a Phase 3 trial in Q4 2025. Q4 net product revenue reached $201M, surpassing estimates, with Wakix patient count rising to 7,100, up by 300 sequentially.
Axsome Q4 Loss Wider Than Expected, Auvelity Drives Sales Growth
AXSM's fourth-quarter 2024 earnings miss estimates while revenues beat the same. Net product sales rise year over year.
HRMY or ONC: Which Is the Better Value Stock Right Now?
HRMY vs. ONC: Which Stock Is the Better Value Option?
Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues
AGIO reports mixed fourth-quarter 2024 results. Its sole marketed drug, Pyrukynd, drives revenues year over year.
Here is Why Growth Investors Should Buy Harmony Biosciences ( HRMY ) Now
Harmony Biosciences (HRMY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Alkermes' Q4 Earnings & Revenues Surpass Estimates, Stock Up
ALKS reports better-than-expected fourth-quarter 2024 results. Net sales of proprietary products increase year over year. Shares rise.
Sage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/Y
SAGE's earnings and revenues miss estimates in the fourth quarter of 2024. The company focuses on the commercialization of depression drug Zurzuvae.
VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Vertex reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Trikafta/Kaftrio drive year-over-year sales.
INCY's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Incyte reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Jakafi and Opzelura drive year-over-year sales.
Insmed's NDA for Lung Disease Drug Gets FDA's Priority Review
The FDA accepts and grants priority review to INSM's NDA for brensocatib to treat patients with non-cystic fibrosis bronchiectasis. A decision is due on Aug. 12, 2025.
RZLT Shares Rise 30.8% in 6 Months: What's Driving the Rally?
Rezolute rides on robust clinical development activity for lead candidate ersodetug (RZ358) for treating hypoglycemia caused by hyperinsulinism.
Are Investors Undervaluing Harmony Biosciences ( HRMY ) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
CHMP Gives Nod to Expanded Use of J&J's Rybrevant & AZN's Imfinzi
The CHMP recommends approval for JNJ's subcutaneous formulation of Rybrevant in NSCLC and AstraZeneca's Imfinzi in limited-stage small-cell lung cancer.
VRTX Gets FDA Nod for Non-Opioid Pain Drug Journavx, Shares Up
The FDA approves Vertex's non-opioid oral pain signal inhibitor, Journavx, for treating adults with moderate-to-severe acute pain. Shares rise.
Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises
The FDA approves AXSM's Symbravo for the acute treatment of migraine with or without aura in adults. The latest nod diversifies its commercial portfolio.
Wall Street Analysts Predict a 28.98% Upside in Harmony Biosciences ( HRMY ) : Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 29% in Harmony Biosciences (HRMY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
HRMY vs. RGEN: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. ( HRMY Quick QuoteHRMY - ) and Repligen ( RGEN Quick QuoteRGEN - ) . But which of these two stocks presents investors with the better value opportunity right now?
FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases
The FDA clears ALLO's investigational new drug application to start clinical studies on its investigational CAR T product, ALLO-329, for autoimmune diseases.
MRK's sNDA for Welireg in Rare Tumors Gets FDA's Priority Tag
The FDA accepts and grants priority review to Merck's sNDA for Welireg to treat advanced pheochromocytoma and paraganglioma. A decision is due on May 26, 2025.
SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up
Sage Therapeutics turns down Biogen's offer to buy the remaining stake in the company and is evaluating strategic alternatives to maximize shareholder value.
MRK Reports Mixed Keytruda Combo Study Data in Gastroesophageal Cancer
The LEAP-015 study is evaluating Merck's Keytruda and Eisai's Lenvima plus chemotherapy in certain types of gastroesophageal adenocarcinoma.
Is it a Good Idea to Invest in Beam Therapeutics Stock Now?
Here, we discuss some reasons why investing in BEAM stock now may turn out to be a prudent move.
4 High Earnings Yield Value Stocks to Buy as Trump Resumes Presidency
Unlock your portfolio value with high earnings yield value stocks like HRMY, NGVT, GPOR and PBI.
Should Value Investors Buy Harmony Biosciences ( HRMY ) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why Harmony Biosciences ( HRMY ) Might be Well Poised for a Surge
Harmony Biosciences (HRMY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
How Much Upside is Left in Harmony Biosciences ( HRMY ) ? Wall Street Analysts Think 39.48%
The mean of analysts' price targets for Harmony Biosciences (HRMY) points to a 39.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
